Elke Wynberg1, Eleri Williams2,3, Gareth Tudor-Williams2,4, Hermione Lyall2,4, Caroline Foster2,4. 1. The Family Clinic, Imperial College Healthcare NHS Trust, St Mary's Hospital, Praed Street, London, UK. elke.wynberg@stcatz.ox.ac.uk. 2. The Family Clinic, Imperial College Healthcare NHS Trust, St Mary's Hospital, Praed Street, London, UK. 3. Department of Paediatric Infectious Diseases and Immunology, Great North Children's Hospital, Newcastle-upon-Tyne, UK. 4. Section of Paediatrics, Division of Infectious Diseases, Imperial College London, London, UK.
Abstract
BACKGROUND: Efavirenz, a non-nucleoside reverse transcriptase inhibitor (NNRTI) is used globally as first-line antiretroviral therapy (ART) in combination with a dual nucleoside backbone in adults and children from 3 years of age. Up to 40% of adults taking efavirenz report central nervous system (CNS) adverse effects, and the rates of discontinuation of efavirenz-based treatment are higher than other first-line regimens. Data on efavirenz discontinuation are more limited for children and adolescents. OBJECTIVE: In this study, we aimed to describe our single-centre paediatric experience of efavirenz. METHODS: Retrospective case-note audit of children and adolescents with perinatally acquired HIV who ever received efavirenz. RESULTS: From 1998 and 2014, 51 children and adolescents aged ≤ 18 years received efavirenz-based treatment. Median age at efavirenz initiation was 9.4 years (interquartile range [IQR] 7-13). More than half (30/51; 59%) subsequently switched off efavirenz-15 (29%) following virological failure with NNRTI-associated resistance mutations, and 16 (30%) after reporting adverse effects. Of those who experienced adverse effects, one-fifth (19.6%) described CNS adverse effects, including sleep disturbance, reduced concentration, headaches, mood change and psychosis. Four children (three males) developed gynaecomastia, two developed hypercholesterolaemia, and one child developed Stevens-Johnson syndrome. Comparison between those reporting side effects and the rest of the cohort showed no difference in age, sex, initial CD4 cell count, viral suppression, length of efavirenz-based treatment, weight, or efavirenz dose per kilogram. Median time to switch was 25 months (IQR 10-71) in those who experienced side effects and 22 months (IQR 12-50) for virological failure. One individual experienced both virological failure and adverse effects. CONCLUSION: Almost two-thirds of this paediatric cohort switched from efavirenz-based treatment to an alternative regimen, due in equal proportions to both virological failure and toxicity. The majority of side effects involved the CNS. First-line regimens with improved tolerability and a higher genetic barrier to resistance should be the preferred option for children.
BACKGROUND:Efavirenz, a non-nucleoside reverse transcriptase inhibitor (NNRTI) is used globally as first-line antiretroviral therapy (ART) in combination with a dual nucleoside backbone in adults and children from 3 years of age. Up to 40% of adults taking efavirenz report central nervous system (CNS) adverse effects, and the rates of discontinuation of efavirenz-based treatment are higher than other first-line regimens. Data on efavirenz discontinuation are more limited for children and adolescents. OBJECTIVE: In this study, we aimed to describe our single-centre paediatric experience of efavirenz. METHODS: Retrospective case-note audit of children and adolescents with perinatally acquired HIV who ever received efavirenz. RESULTS: From 1998 and 2014, 51 children and adolescents aged ≤ 18 years received efavirenz-based treatment. Median age at efavirenz initiation was 9.4 years (interquartile range [IQR] 7-13). More than half (30/51; 59%) subsequently switched off efavirenz-15 (29%) following virological failure with NNRTI-associated resistance mutations, and 16 (30%) after reporting adverse effects. Of those who experienced adverse effects, one-fifth (19.6%) described CNS adverse effects, including sleep disturbance, reduced concentration, headaches, mood change and psychosis. Four children (three males) developed gynaecomastia, two developed hypercholesterolaemia, and one child developed Stevens-Johnson syndrome. Comparison between those reporting side effects and the rest of the cohort showed no difference in age, sex, initial CD4 cell count, viral suppression, length of efavirenz-based treatment, weight, or efavirenz dose per kilogram. Median time to switch was 25 months (IQR 10-71) in those who experienced side effects and 22 months (IQR 12-50) for virological failure. One individual experienced both virological failure and adverse effects. CONCLUSION: Almost two-thirds of this paediatric cohort switched from efavirenz-based treatment to an alternative regimen, due in equal proportions to both virological failure and toxicity. The majority of side effects involved the CNS. First-line regimens with improved tolerability and a higher genetic barrier to resistance should be the preferred option for children.
Authors: Jan Gerstoft; Ole Kirk; Niels Obel; Court Pedersen; Lars Mathiesen; Henrik Nielsen; Terese L Katzenstein; Jens D Lundgren Journal: AIDS Date: 2003-09-26 Impact factor: 4.177
Authors: M Fabbiani; M Zaccarelli; A Latini; G Sterrantino; G D'Ettorre; P Grima; A Mondi; B Rossetti; B Borchi; M Giuliani; A Antinori; A De Luca; S Di Giambenedetto Journal: HIV Med Date: 2015-09-22 Impact factor: 3.180
Authors: Jens D Lundgren; Abdel G Babiker; Fred Gordin; Sean Emery; Birgit Grund; Shweta Sharma; Anchalee Avihingsanon; David A Cooper; Gerd Fätkenheuer; Josep M Llibre; Jean-Michel Molina; Paula Munderi; Mauro Schechter; Robin Wood; Karin L Klingman; Simon Collins; H Clifford Lane; Andrew N Phillips; James D Neaton Journal: N Engl J Med Date: 2015-07-20 Impact factor: 91.245
Authors: Sophie Abgrall; Suzanne M Ingle; Margaret T May; Dominque Costagliola; Patrick Mercie; Matthias Cavassini; Joanne Reekie; Hasina Samji; M John Gill; Heidi M Crane; Jan Tate; Timothy R Sterling; Andrea Antinori; Peter Reiss; Michael S Saag; Michael J Mugavero; Andrew Phillips; Christian Manzardo; Jan-Christian Wasmuth; Christoph Stephan; Jodie L Guest; Juan Luis Gomez Sirvent; Jonathan A C Sterne Journal: AIDS Date: 2013-03-13 Impact factor: 4.177
Authors: David W Haas; Yuki Bradford; Anurag Verma; Shefali S Verma; Joseph J Eron; Roy M Gulick; Sharon A Riddler; Paul E Sax; Eric S Daar; Gene D Morse; Edward P Acosta; Marylyn D Ritchie Journal: Pharmacogenet Genomics Date: 2018-07 Impact factor: 2.089